Continued Malignant Cell Proliferation in Head and Neck Tumors during Cytotoxic Therapy

Clinical Cancer Research

Volumn 2, Issue 9, 1996, Pages 1453-1460

  Preisler, Harvey D ^a   Kotelnikov, Valery M ^a   LaFollette, Suzanne ^a   Taylor IV, Samuel ^a   Mundle, Suneel ^a   Wood, Nancy ^b   Coon IV, John S ^b   Hutchinson, James ^b   Panje, William ^b   Caldarelli, David D ^b   Griem, Katherine ^b  

^a RUSH CANCER INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOPSY; CELL COUNT; CELL CYCLE S PHASE; CELL DIVISION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MOUTH MUCOSA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION EXPOSURE; SQUAMOUS CELL CARCINOMA; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL DIVISION; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH MUCOSA; PACLITAXEL; S PHASE; TIME FACTORS;

EID: 0030222997     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Withers, H. R., Taylor, J. M. G., and Maciejewski, B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol., 27: 131-146, 1988.
2. Trott, K., and Kummermelur, J. What is known about tumor proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother. Oncol., 3: 1-9, 1985
3. Tubiana, M. Repopulation in human tumors. A biological background for fractionation in radiotherapy Acta Oncol , 27 83-88, 1988.
4. Kummermehr, J., Dörr, W., and Trott, K. R. Kinetics of accelerated repopulation in normal and malignant squamous epithelia during fractionated radiotherapy. Radiation science of molecules, mice and men Br. J Radiol. Suppl., 24: 193-199, 1992.
5. Bentzen, S. M., and Thames, H. D. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother. Oncol., 22: 161-166, 1991.
6. Peters, L., Ang, K., and Thames, H Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol., 27. 185-194, 1988.
7. Bourhis, J., Wilson, G., Wibault, P., Janot, P., Bosq, J., Armand, J. P., Luboinski, B., Malaise, E. P., and Eschwege, F. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer Laryngoscope, 104. 468-472, 1994.
8. Hermens A. F., and Barendsen, G. W. Changes of cell proliferation characteristics in a rat rabdomyosarcoma before and after X-irradiation. Eur. J. Cancer, 5: 173-189, 1969.
9. Ramsay, J., Suit, H. D., Preffer, F I., and Sedlacek, R. Changes in bromodeoxyuridine labeling index during radiation treatment of an experimental tumor. Radiat. Res., 116: 453-461, 1988.
10. Rockwell, S., and Kallman, R. F. Cyclic radiation-mduced variations in cellular sensitivity in a mouse mammary tumor. Radiat. Res., 57: 132-147, 1974.
11. Braunschweiger, P G., Schenken L. L., and Schiffer, L M. The cytokinetic basis for the design of efficacious radiotherapy protocols. Int. J. Radiat. Oncol. Biol. Phys., 5. 37-47, 1979.
12. Ang, K. K., and Peters, L. J. Altered fractionation in radiation oncology. Princ. Pract. Oncol. 8: 1-15, 1994.
13. Preisler, H., and Gopal, V. Regrowth resistance in leukemia and lymphoma, the need for a new system to classify treatment failure and for new approaches to treatment. Leuk. Res, 18: 149-160, 1994.
14. Courdi, A, Tubiana, M., Chavaudra, N., and Malaise, E. P. Changes in labeling indices of human tumors after irradiation. Int. J. Radiat. Oncol Biol. Phys., 6: 1639-1644, 1980.
15. Silvestrini, R., Molinari, R., Costa, A., Volterrani, F., and Gardani, G. Short-term variation in labeling index as a predictor of radiotherapy response in human oral cavity carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 10: 965-970, 1984.
16. Elequin, F. T., Muggia, F. M., Ghossein, N A., Ager, P. J., and Krisnaswamy, V. Correlation between in vitro labeling indices (LIs) and tumor regression following radiotherapy. Int. J. Radiat. Oncol. Biol. Phys, 4: 207-213, 1978.
17. Preisler, H. D., Raza, A., and Larson, R. Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. Blood, 80: 2600-2603, 1992.
18. Taylor, S. G., Murthy, A. K., Vannetzel, J-M., Colin, P., Dray, M., Caldarelli, D. D , Shott, S., Yokes, E., Showel, J. L., Hutchinson, J. C., Witt, T. R., Griem, K. L., Hartsell, W. F., Kies, M. S., Mittal, B , Rebischung, J-L., Coupez, D. J., Desphieux, J-L., Bobin, S., and LePajolec, C. Randomized comparison of neoadjuvant cisplatin and fiuorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J. Clin. Oncol., 12: 383-395, 1994.
19. Kotelnikov, V. M., Coon, J., Haleem, A., Taylor, S., Hutchinson, J., Panje, W., Caldarelli, D., and Preisler, H D. Cell kinetics of head and neck cancers. Clin. Cancer Res., 1: 527-537, 1995.
20. Raza, A., Mundle, S., Ifticar, A., Gregory, S., Marcus, B., Khan, Z., Alvi, S , Shetty, V., Dameron, S., Wright, V., Adler, S., Loew, J., Shott, S., Ali, N., and Preisler, H. D. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am. J. Hematol., 48: 143-154, 1995.
21. Fowler, J. F. Apparent rates of proliferation of acutely responding normal tissues during radiotherapy of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 21: 1451-1456, 1991.
22. Gabutti, V., Pileri, A., Tarocco, R. P., Gavosto, F., and Cooper, E. H. Proliferative potential of out-of-cycle leukemic cells. Nature (Lond.), 224: 375-376, 1969.
23. Preisler, H. D, Raza, A., Larson, R., Godberg, J., Ticot, G., Carey, M., and Kukla, C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. Leuk. Res., 15: 773-780, 1991.
24. Raza, A., Yousuf, N., Bokhari, S. A. J., Abbas, A., Lampkin, B., Pancoast, J., Bismayer, J., Siegrist, C., Browman, G., Bennett, J., Goldberg, J., Grunwald, H., Larson, R., Tricot, G., Vogler, R., Gartside, P., and Preisler, H. D. Cell cycle characteristics: alterable determinant of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid leukemia. Int J. Oncol., 2: 301-307, 1993.
25. Begg, A., Hofland, I., Van Glabekke, M., Bartelink, H., and Horiot, G. Predictive value of potential doubling time for radiotherapy of head and neck patients: results from the EORTC cooperative trial 22851. Semin. Radiat. Oncol., 2: 22-25, 1992.
26. Corvo, R., Giaretti, W , Sanguineti, G., Geido, E , Orecchia, R., Guenzi, M., Margarino, G., Bacigalupo, A., Garaventa, G., Barbieri, M., and Vitale, V. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy resimen. J Clin Oncol., 13. 1843-1850, 1995.
27. Meyer, J. C., and Lee, J. Y. Relationship of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor count, therapeutic responsiveness, and duration of survival. Cancer Res., 40: 1890-1896, 1980
28. Christensson, B., Tribucant, B., Linden, I. L., Ullman, B., and Biberfeld, P Cell proliferation and DNA content in non-Hodgkin's lymphoma Cancer (Phila.), 58: 1295-1304, 1986.
29. Preisler, H. D., Raza, A., Bonomi, P., Taylor, S., LaFollette, S., Leslie, W., and Lincoln, S. Regrowth resistance is a likely significant contribution to treatment failure in drug sensitive neoplastic diseases. Cancer Invest., in press, 1996.
30. Preisler, H. D. Resistance to cytotoxic therapy. A speculative overview. Ann Oncol., 6. 651-657, 1995